Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
Active Biotech has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism (EULAR), an international event for specialists in the field of rheumatology, held in Copenhagen June 10-13. The patients in the Phase Ib trial were treated daily for 12 weeks with 57-57. The maximum tolerable dose was, as earlier communicated, defined at 4.5 mg/day. [more...]
|
|
|
